Pozen Inc. v. Par Pharmaceutical, Inc., No. 6:08-cv-00437 (E.D. Tex. June 18, 2010)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This Memorandum Opinion and Order sets forth the Court’s constructions for the disputed claim terms in the patents asserted by Plaintiff Pozen Inc. (“Pozen”). Pozen asserts U.S. Patent Nos. 6,060,499 (“the ‘499 patent”), 6,586,458 (“the ‘458 patent”), and 7,332,183 (“the ‘183 patent”) and has filed an Opening Claim Construction Brief (Doc. No. 164) (“Opening”), as well as a Reply in support of Pozen’s proposed constructions (Doc. No. 176) (“Reply”). Defendants Par Pharmaceutical, Inc., Alphapharm Pty Ltd., and Dr . Reddy’s Laboratories, Inc.